Weekly headlines from Pharmaprojects
Week beginning 11th December 2006
- 80 new chemical entities, formulations and biologicals reported
- Austrian firm Pelias to tackle nosocomial infections
- Oral immunotherapy the focus for Denmark’s Curalogic
- Novel anticancer target identified at SuperGen
- Novartis highlights a dozen new R&D candidates
- Partners sought for ReceptIcon’s megalin antagonists
- Pfizer’s CETP inhibitor loss overshadows new drugs added to pipeline
- Wockhardt withdraws its recombinant insulin
- Nycomed to work with Durect on POSIDUR
- Kinesin inhibitor deal between GSK and Cytokinetics modified
- UK launch for Champix
- 4SC starts Phase II trials for DHODH inhibitor
Top
Week beginning 4th December 2006
- 48 new chemical entities, formulations and biologicals reported
- Danish firm Meabco combining ligands with metal salts
- Ambit discloses leads for its kinase inhibitor programmes
- Pim-1 kinase a new oncology target for SuperGen
- Five further Phase II failures announced
- Roche licenses-in two anticancers
- Boehringer Ingelheim and Biota form alliance for hepatitis-C
- Pfizer pulls out of asenapine deal
- Emselex launched in the UK
- EU approval for Byetta
- First filings for Novartis’ CML therapy
- Organon moves two into higher clinical phase and three into the pipeline
Top
Week beginning 27th November 2006
- 40 new chemical entities, formulations and biologicals reported
- Neuralstem developing stem cell therapies for ALS and ISP
- Macular degeneration the focus for new US firm Acucela
- Introgen identifies novel chemosensitizing target
- Partners sought by Spirogen
- Astion drops two candidates
- Sosei’s RA therapy fails to show Phase II efficacy
- Grazax launched in Germany
- EU approval and first European launches for Sprycel
- Immtec receives orphan drug status for PCP treatment
- Phase III trials for Medicure’s anti-ischaemic
- Seattle begins clinical studies for Hodgkin’s immunoconjugate
Top
Week beginning 20th November 2006
- 28 new chemical entities, formulations and biologicals reported
- Bellicum developing ex vivo gene therapy for prostate cancer
- Raptor identifies new target for cancer and osteoporosis
- Starpharma seeking partners for anti-infective dendrimers
- Celera confirms move to diagnostics only
- Daiichi drops two clinical projects
- Corautus’ angina gene therapy discontinued
- Stability issues force suspension of anthrax vaccine trials
- Wyeth licenses-in Ablynx’ anti-TNF-α nanobodies
- Spectrum selective kinase inhibitors picked up by GSK
- EU approval for Mydocalm
- Melanin concentrating hormone-1 receptor antagonist enters the clinic at Neurogen
Top
Week beginning 13th November 2006
- 50 new chemical entities, formulations and biologicals reported
- Illumigen seeking to exploit beneficial mutations for drug development
- Genzyme acquires AnorMED
- Memory seeking partners for cognition enhancers
- Japanese neuropathy inhibitor dropped after Phase II failure
- Leo licenses in TopoTarget’s antipsoriatic
- Takeda completes its withdrawal from Tavocept agreement…
- …but launches Duetact for diabetes
- UK the first market for Thelin
- Prexige gets EU and Canadian approvals in COX-2 comeback
- Introgen files for first European gene therapy approval
- Phase II trials for Athena’s vulnerary among news from BioPartnering Europe
Top
If you are interested in learning more about Pharmaprojects why not visit our
demo today! Alternatively you can contact Nicholas Johnston, Marketing Executive to assist with any queries.
Ian Lloyd,
Managing Editor
Telephone +44 (0)20 7017 6886
Facsimile +44 (0)20 7017 6898
|
.gif)
